BioCentury | Jul 14, 2014
Company News

Proteostasis Therapeutics Inc management update

...Neurology Hired: Meenu Chhabra as president, CEO and a director, formerly president and CEO of Allozyne Inc. WIR...
BioCentury | Feb 3, 2014
Finance

Bicoastal incubation

...and sold their assets for undisclosed amounts. Among Accelerator's active graduates are protein therapeutics play Allozyne Inc....
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

...Redwood uses an aldehyde tag incorporated into the mAb (see BioCentury, Aug. 1, 2011) . Allozyne Inc....
...Companies and Institutions Mentioned ADC Therapeutics S.a.r.l. , Lausanne, Switzerland Adimab LLC , Lebanon, N.H. Allozyne Inc....
...Medicine Co. Ltd. (Shanghai:600216), Zhejiang, China Tables Next generation ADCs Company Technology Status Site-specific conjugation Allozyne Inc....
BioCentury | Mar 11, 2013
Company News

Integrated Diagnostics management update

...Diagnostics Inc. , Seattle, Wash. Business: Diagnostic Hired: John Bencich as CFO, formerly CFO of Allozyne Inc. WIR...
BioCentury | Jul 9, 2012
Tools & Techniques

Taking ADCs beyond oncology

...Other companies developing site-specific ADCs with unnatural amino acids include Sutro Biopharma Inc. and Allozyne Inc. Allozyne's...
...and one unpartnered antibody-peptide conjugate. All three are in preclinical development. Companies and Institutions Mentioned Allozyne Inc....
BioCentury | May 28, 2012
Finance

Pressing the Accelerator

...remaining six deals, Weissman said. He added that only two investments - protein therapeutics play Allozyne Inc....
...inflammation play VLST Corp. ; infectious disease and inflammation company Theraclone Sciences Inc. ; and Allozyne...
BioCentury | Jan 9, 2012
Company News

Poniard cancer news

...OTCQB under "PARD." The company plans to list on the OTC Bulletin Board. Last month, Allozyne Inc....
BioCentury | Jan 2, 2012
Company News

Allozyne, Poniard deal

...board is exploring alternatives for the company and its assets (see BioCentury, June 27, 2011). Allozyne Inc....
BioCentury | Oct 31, 2011
Clinical News

AZ01: Phase Ib data

...showed that various doses of AZ01 given at 14- or 28-day intervals were well tolerated. Allozyne...
...of AZ01 were well tolerated at all 5 dose levels tested (see BioCentury, Jan. 17). Allozyne Inc....
BioCentury | Sep 12, 2011
Financial News

Poniard financial update

...enough to allow the stock to trade above $4; completion of Poniard's planned merger with Allozyne Inc....
Items per page:
1 - 10 of 19
BioCentury | Jul 14, 2014
Company News

Proteostasis Therapeutics Inc management update

...Neurology Hired: Meenu Chhabra as president, CEO and a director, formerly president and CEO of Allozyne Inc. WIR...
BioCentury | Feb 3, 2014
Finance

Bicoastal incubation

...and sold their assets for undisclosed amounts. Among Accelerator's active graduates are protein therapeutics play Allozyne Inc....
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

...Redwood uses an aldehyde tag incorporated into the mAb (see BioCentury, Aug. 1, 2011) . Allozyne Inc....
...Companies and Institutions Mentioned ADC Therapeutics S.a.r.l. , Lausanne, Switzerland Adimab LLC , Lebanon, N.H. Allozyne Inc....
...Medicine Co. Ltd. (Shanghai:600216), Zhejiang, China Tables Next generation ADCs Company Technology Status Site-specific conjugation Allozyne Inc....
BioCentury | Mar 11, 2013
Company News

Integrated Diagnostics management update

...Diagnostics Inc. , Seattle, Wash. Business: Diagnostic Hired: John Bencich as CFO, formerly CFO of Allozyne Inc. WIR...
BioCentury | Jul 9, 2012
Tools & Techniques

Taking ADCs beyond oncology

...Other companies developing site-specific ADCs with unnatural amino acids include Sutro Biopharma Inc. and Allozyne Inc. Allozyne's...
...and one unpartnered antibody-peptide conjugate. All three are in preclinical development. Companies and Institutions Mentioned Allozyne Inc....
BioCentury | May 28, 2012
Finance

Pressing the Accelerator

...remaining six deals, Weissman said. He added that only two investments - protein therapeutics play Allozyne Inc....
...inflammation play VLST Corp. ; infectious disease and inflammation company Theraclone Sciences Inc. ; and Allozyne...
BioCentury | Jan 9, 2012
Company News

Poniard cancer news

...OTCQB under "PARD." The company plans to list on the OTC Bulletin Board. Last month, Allozyne Inc....
BioCentury | Jan 2, 2012
Company News

Allozyne, Poniard deal

...board is exploring alternatives for the company and its assets (see BioCentury, June 27, 2011). Allozyne Inc....
BioCentury | Oct 31, 2011
Clinical News

AZ01: Phase Ib data

...showed that various doses of AZ01 given at 14- or 28-day intervals were well tolerated. Allozyne...
...of AZ01 were well tolerated at all 5 dose levels tested (see BioCentury, Jan. 17). Allozyne Inc....
BioCentury | Sep 12, 2011
Financial News

Poniard financial update

...enough to allow the stock to trade above $4; completion of Poniard's planned merger with Allozyne Inc....
Items per page:
1 - 10 of 19